Drugs / RO7446603
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06850922 | Jun 2022 → May 2026 | diabetic macular edema | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7446603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06850922 ↗ |
| Route | Intravitreal | “RO7446603 as an IVT injection” NCT06850922 ↗ |